Riskpilot← Back to searchSign inGet full accessOxyPharma AB
ABActiveOrg 5566089958Drottninggatan 29Research and experimental development on natural sciences and engineering · NACE 7210Est. 20010 employees
Revenue 2024
SEK 0
EBITDA margin
—
+11% vs 2023
Equity ratio
95.3%
Financial strength
Net profit 2024
SEK -624K
+43% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -17K | +11% |
| Net profit | SEK -624K | +43% |
| Total assets | SEK 172K | -79% |
| Equity | SEK 164K | -79% |
| Employees | 0 | — |
Legal name
OxyPharma AB
Org number
5566089958
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 mars 2001
Share capital
SEK 421 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva forskning och utveckling av läkemedel ävensom idka därmed förenlig verksamhet.
Address
Drottninggatan 29
Phone
+4687261700
Email
monica.sander@banqit.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −11 | −15 | −14 | −19 | −17 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −11 | −15 | −14 | −19 | −17 |
| Net financials | 3 282 | −9 626 | −4 761 | −2 156 | −1 214 |
| Profit before tax | 3 271 | −4 802 | −2 384 | −1 097 | −624 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 3 271 | −4 802 | −2 384 | −1 097 | −624 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 379 | 3 577 | 1 193 | 802 | 172 |
| Equity | 8 371 | 3 569 | 1 185 | 788 | 164 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 8 | 8 | 8 | 14 | 8 |
| Total debt | 8 | 8 | 8 | 14 | 8 |
EBITDA margin
-1700000.0%
This company
15.8%
Market median
-10759594% vs market
20202024
Equity ratio
95.3%
This company
38.2%
Market median
+149% vs market
20202024
Return on equity
-380.5%
This company
18.4%
Market median
-2168% vs market
20202024
Net profit margin
-62400000.0%
This company
8.1%
Market median
-770370470% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2026 | |
| Former (1) | ||
| Board of Directors | 2022 – 2026 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 95% | 95% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LLD Nybohov Invest Aktiebolag
OxyPharma AB Board members of OxyPharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Monica Elisabeth Sander | Deputy Board Member | 0 companies |
| Anna Ulrika Lundblad | Board of Directors | 0 companies |
| Leif Jörgen Ingemar Lundblad | Board of Directors | 0 companies |